As part of the Old Strategy’s expansion and ongoing fundraising efforts, the company is sharing insights into the exciting world of recipients and why they should be targeted as their own drugs. The paper also explains how to create benefits for patients with a variety of symptoms in a highly unsatisfactory manner.
Docobot, Inc., A company that specializes in gastrointestinal (GI) disease technology, has announced the closure of a series of rounds today. In partnership with Finance, the company acquired Andrew J. Ritter. In 2020, he led the sale of Retail Pharmaceuticals (NASDAQ: RTTR) and appointed him CEO.
Andrew received an MBA from the University of Pennsylvania at Warton School and has more than 16 years of experience with GI.
Andrew Ninh, CEO of Dokobot, continues to be the Chief Strategic Officer, leading business development, strategic partnerships and innovation.
The company recently closed its $ 4 million series led by Case Ventures, and has invested in Bright Capital Partners, Partnership Fund and Boutique Venture Partnerships, totaling $ 8.5 million since its inception.
Doctotic diagnostic tool UTIVII uses artificial intelligence for automated GI diagnosis. The new capital will be used to promote clinical trials and FDN screening. To read more Click here.
Central Florida Health System Adventheads And Sema4Using AI for information-based insights, a patient-oriented health intelligence company is currently collaborating on the development of a new Adventure Genomics and Personalized Health Program to provide research insights and prevent, diagnose and treat disease in their patients.
Dr. Steven, Chief Scientific Officer of AdventHealth, said: “Adventhel is committed to the importance of genomics and personal medicine for health and well-being in the future, and we are pleased to be working with Sema 4. This technology and collaboration will enable us to translate more clinical, genetic, and other patient information into finding and delivering life-saving treatments to patients who have not previously had access to these options. To read more Click here.
New Mexico Cancer Center Has announced a strategic partnership with Deep lens, A biotech company that implements AI for clinical trial recruitment. NMCCN-based ICI. Based on clinical trial testing and enrollment solution, VIPER ወደ is transferred to NMCM.
VIR uses proprietary, cloud-based technology to facilitate, identify and accelerate the clinical trial recruitment process. Through this collaboration, NCMC will be able to better identify, refine, and integrate clinical trials based on patients with oncology. To read more Click here.
Picture Akindo, Getty Images
Disclaimer: The opinions expressed within this article are the personal opinions of the author. The facts and opinions appearing in the article do not reflect the views of knews.uk and knews.uk does not assume any responsibility or liability for the same.